Urologists at Vanderbilt Health are enrolling men with stress urinary incontinence (SUI) in a clinical trial named SOPHIA2 to assess the safety and efficacy of the UroActive implant, following an ...

Urologists at Vanderbilt Health are enrolling men with stress urinary incontinence (SUI) in a clinical trial named SOPHIA2 to assess the safety and efficacy of the UroActive implant, following an ...

Molecular profiling of tumors has been shown to improve risk stratification, and it may be useful for prostate cancer active surveillance.

Vanquish uses ultrasound, transurethral and electromagnetically guided thermotherapy to ablate prostate tissue.

Novel biodegradable patent foramen ovale (PFO) closure devices offer a promising therapeutic option. The efficacy and safety of the novel biodegradable devices compared with nitinol devices have not ...

Abstract: This study presents groundbreaking advancements in complementary field-effect transistor (CFET) technology, achieving two key milestones: the demonstration of the first fully functional ...

The patient and local surgical team were located in Gibraltar, about 2,400 kilometers (about 1,500 miles) away. The procedure ...

MINNEAPOLIS, March 5, 2026 /PRNewswire/ — Francis Medical, Inc., a privately held medical device company, announced today the successful completion of the first commercial (non-clinical trial) ...

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, ...

Executives from Oric Pharmaceuticals (NASDAQ:ORIC) used a conference discussion to highlight near-term clinical catalysts for its two lead oncology programs and to outline how upcoming data could ...

A drug for advanced prostate cancer has shown "remarkable" results in an early-stage trial, experts have said.

The new drug, known as VIR-5500, uses a so-called cloaking device and only activates when it reaches the tumour ...